Lupin gets tentative nod from USFDA for Efinaconazole Topical Solution

Efinaconazole Topical Solution, 10% is indicated for the topical treatment of onychomycosis of the toenail(s)

53
USFDA
Picture: Pixabay

Last Updated on December 27, 2020 by The Health Master

Lupin has received tentative approval for its Efinaconazole Topical Solution, 10%, from the United States Food and Drug Administration (USFDA), to market a generic equivalent of Jublia Topical Solution, 10%, of Bausch Health Americas.

Efinaconazole Topical Solution, 10% is indicated for the topical treatment of onychomycosis of the toenail(s) due to Trichophyton rubrum and Trichophyton mentagrophytes.

Efinaconazole Topical Solution, 10%,(RLD: Jublia) had estimated annual sales of $222.9 million in the US (IQVIA MAT September 2020).


The Health Master is now on Telegram. For latest update on health and Pharmaceuticals, subscribe to The Health Master on Telegram.

Follow and connect with us on Facebook, Linkedin